Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 10:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 1,260 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: I-START Clear all
Completed Phase 1Phase 2 Interventional Results available

Vaccine Therapy in Treating Patients With Stage IV Breast Cancer

NCT00791037
View directory record Official record
Conditions
HER2-positive Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
Interventions
HER-2/neu peptide vaccine, leukapheresis, ex vivo-expanded HER2-specific T cells, cyclophosphamide, sargramostim, laboratory biomarker analysis
Biological · Procedure · Drug + 1 more
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 25, 2017 · Synced Oct 31, 2026, 10:32 PM EDT
Completed Phase 1Phase 2 Interventional Results available

VEGF Trap and Docetaxel in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

NCT00436501
View directory record Official record
Conditions
Fallopian Tube Cancer, Malignant Tumor of Peritoneum, Recurrent Ovarian Epithelial Cancer
Interventions
docetaxel, ziv-aflibercept, laboratory biomarker analysis, pharmacological study
Drug · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
2
States / cities
Houston, Texas • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Oct 31, 2026, 10:32 PM EDT
Completed Phase 1 Interventional

CPT-11/Cisplatin and Celecoxib With Radiation Therapy for Patients With Unresectable Non-Small Cell Lung Cancer (NSCLC)

NCT00346801
View directory record Official record
Conditions
Lung Cancer
Interventions
Celecoxib, Cisplatin, CPT-11, Concurrent Thoracic Radiation Therapy
Drug · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 22, 2012 · Synced Oct 31, 2026, 10:32 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma

NCT07336472
View directory record Official record
Conditions
Multiple Myeloma
Interventions
IBI3003
Drug
Lead sponsor
Fortvita Biologics (USA)Inc.
Industry
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
6
States / cities
Scottsdale, Arizona • Duarte, California • Irvine, California + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 31, 2026, 10:32 PM EDT
Completed Phase 2 Interventional

Chemotherapy Plus Monoclonal Antibody Therapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Overexpresses HER2

NCT00003992
View directory record Official record
Conditions
Breast Cancer
Interventions
trastuzumab, cyclophosphamide, doxorubicin hydrochloride, paclitaxel, tamoxifen citrate
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2009
U.S. locations
44
States / cities
Palo Alto, California • Stanford, California • Denver, Colorado + 35 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2013 · Synced Oct 31, 2026, 10:32 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Ifosfamide, Carboplatin, Etoposide, and SGN-30 in Treating Young Patients With Recurrent Anaplastic Large Cell Lymphoma

NCT00354107
View directory record Official record
Conditions
Anaplastic Large Cell Lymphoma, Recurrent Childhood Anaplastic Large Cell Lymphoma
Interventions
monoclonal antibody SGN-30, therapeutic hydrocortisone, ifosfamide, carboplatin, etoposide, methotrexate, cytarabine, pharmacological study, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 21 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 14, 2018 · Synced Oct 31, 2026, 10:32 PM EDT
Completed Phase 2 Interventional

A Study of Canakinumab With Chemotherapy, Radiation Therapy, and Durvalumab in People With Lung Cancer

NCT04905316
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Canakinumab, Durvalumab, Radiation therapy, Chemotherapy
Drug · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 31, 2026, 10:32 PM EDT
Completed Phase 1Phase 2 Interventional

Gefitinib and Radiation Therapy in Treating Patients With Glioblastoma Multiforme

NCT00052208
View directory record Official record
Conditions
Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma
Interventions
gefitinib, radiation therapy, laboratory biomarker analysis
Drug · Radiation · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 30, 2020 · Synced Oct 31, 2026, 10:32 PM EDT
Completed Phase 1 Interventional

Oblimersen, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia

NCT00039117
View directory record Official record
Conditions
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Secondary Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
Interventions
oblimersen sodium, cytarabine, daunorubicin hydrochloride, laboratory biomarker analysis, pharmacological study
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
60 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 4, 2015 · Synced Oct 31, 2026, 10:32 PM EDT
Not listed Phase 1 Interventional

Bortezomib (VELCADE), Cladribine and Rituximab (VCR) in Mantle Cell Lymphoma (PSHCI 10-011)

NCT01439750
View directory record Official record
Conditions
Mantle Cell Lymphoma
Interventions
Rituximab, bortezomib, Cladribine
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
2
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 7, 2017 · Synced Oct 31, 2026, 10:32 PM EDT
Completed Phase 1 Interventional

A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation

NCT01859026
View directory record Official record
Conditions
Lung Cancer, Non-Small Cell Lung Cancer
Interventions
MEK162, Erlotinib
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 19, 2023 · Synced Oct 31, 2026, 10:32 PM EDT
Completed Phase 3 Interventional

Combination Chemotherapy in Treating Patients With Previously Untreated Rhabdomyosarcoma

NCT00003958
View directory record Official record
Conditions
Adult Malignant Mesenchymoma, Adult Rhabdomyosarcoma, Alveolar Childhood Rhabdomyosarcoma, Childhood Malignant Mesenchymoma, Embryonal Childhood Rhabdomyosarcoma, Embryonal-botryoid Childhood Rhabdomyosarcoma, Nonmetastatic Childhood Soft Tissue Sarcoma, Previously Untreated Childhood Rhabdomyosarcoma, Stage I Adult Soft Tissue Sarcoma, Stage II Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma
Interventions
dactinomycin, vincristine sulfate, cyclophosphamide, therapeutic conventional surgery, radiation therapy, topotecan hydrochloride, filgrastim, sargramostim, laboratory biomarker analysis
Biological · Drug · Procedure + 2 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 49 Years
Enrollment
702 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Arcadia, California
Source: ClinicalTrials.gov public record
Updated Jun 17, 2013 · Synced Oct 31, 2026, 10:32 PM EDT
Completed Phase 1 Interventional

Study of Erlotinib and Metformin in Triple Negative Breast Cancer

NCT01650506
View directory record Official record
Conditions
Breast Cancer
Interventions
Metformin, Erlotinib
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 79 Years · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 30, 2017 · Synced Oct 31, 2026, 10:32 PM EDT
Completed Not applicable Interventional

Insulin Start Therapy Application With Resources and Training

NCT03999268
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
I-START, Standard Insulin Administration Education
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 8, 2022 · Synced Oct 31, 2026, 10:32 PM EDT
Completed Phase 1 Interventional

Study of AMD3100 (Plerixafor) and Rituximab in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT00694590
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
Interventions
plerixafor
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
3
States / cities
La Jolla, California • Columbus, Ohio • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 20, 2015 · Synced Oct 31, 2026, 10:32 PM EDT
Completed Phase 1 Interventional Results available

A Phase I Study of Oral Ixabepilone in Subjects With Advanced Cancer

NCT00422097
View directory record Official record
Conditions
Cancer
Interventions
Ixabepilone, 5 mg/d, Ixabepilone, 10 mg/d, Ixabepilone, 15 mg/d, Ixabepilone, 20 mg/d, Ixabepilone, 25 mg/d, Ixabepilone, 30 mg/d, Ixabepilone, 25 mg, with famotidine, Ixabepilone, 25 mg, with food
Drug
Lead sponsor
R-Pharm
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 10, 2016 · Synced Oct 31, 2026, 10:32 PM EDT
Completed Not applicable Interventional

DPP Feasibility Study of Breastfeeding - eMOMS 2.0

NCT06372860
View directory record Official record
Conditions
Overweight or Obesity, Pregnancy
Interventions
Diabetes Prevention Program, Breastfeeding, Usual Care
Behavioral
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Wichita, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 31, 2026, 10:32 PM EDT
Completed Phase 1 Interventional

Evaluating Patients With Impaired Hepatic Function

NCT00398424
View directory record Official record
Conditions
Impaired Hepatic Function
Interventions
S-1/Cisplatin
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
6
States / cities
Scottsdale, Arizona • New Haven, Connecticut • Lexington, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2024 · Synced Oct 31, 2026, 10:32 PM EDT
Recruiting Phase 1 Interventional

Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer

NCT06696768
View directory record Official record
Conditions
Metastatic Colorectal Adenocarcinoma, Stage III Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Unresectable Colorectal Adenocarcinoma
Interventions
Bevacizumab, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Emavusertib, Fluorouracil, Leucovorin Calcium, Magnetic Resonance Imaging, Oxaliplatin, Positron Emission Tomography
Biological · Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
13
States / cities
Gainesville, Florida • Shiloh, Illinois • Fairway, Kansas + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 31, 2026, 10:32 PM EDT
Recruiting Phase 1 Interventional

Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer

NCT05526924
View directory record Official record
Conditions
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Head and Neck Carcinoma, Head and Neck Cancer Stage IV, Head and Neck Cancers - Throat
Interventions
Chemoradiation, Pamiparib, Hydroxyurea, Fluorouracil (5FU), Tislelizumab
Radiation · Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 31, 2026, 10:32 PM EDT
Suspended Phase 1 Interventional

Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab

NCT04266730
View directory record Official record
Conditions
Squamous Cell Lung Cancer, Squamous Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck
Interventions
PANDA-VAC, Pembrolizumab
Biological · Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2033
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 31, 2026, 10:32 PM EDT
Completed Phase 1Phase 2 Interventional

Valganciclovir in Congenital CMV Infants

NCT00031434
View directory record Official record
Conditions
Cytomegalovirus Infections
Interventions
Valganciclovir, Ganciclovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 30 Days
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
21
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2011 · Synced Oct 31, 2026, 10:32 PM EDT
Completed Phase 1 Interventional

Doxil, Bevacizumab and Temsirolimus Trial

NCT00761644
View directory record Official record
Conditions
Advanced Cancer
Interventions
Doxil, Bevacizumab, Temsirolimus
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
12 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 11, 2019 · Synced Oct 31, 2026, 10:32 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

COVID-19: Povidone-Iodine Intranasal Prophylaxis in Front-line Healthcare Personnel and Inpatients

NCT04364802
View directory record Official record
Conditions
COVID-19, SARS-CoV 2
Interventions
Povidone-Iodine Nasal Spray and Gargle
Drug
Lead sponsor
Nikita Gupta
Other
Eligibility
18 Years to 99 Years
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 2, 2022 · Synced Oct 31, 2026, 10:32 PM EDT